Exhibit 99.1 1 SCH Health | --- | --- | |----------------------------|-------| | | | | Investor Contact: | | | Garen Sarafian | | | ir@bauschhealth.com | | | (877) 281-6642 (toll free) | | | --- | --- | |-------------------------------------------|-------| | | | | Media Contact: | | | Katie Savastano | | | corporate.communications@bauschhealth.com | | | (908) 541-3785 | | BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2024 RESULTS • Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBIT ...

Bausch Health Companies Today BHC Bausch Health Companies $8.05 -0.03 (-0.37%) 52-Week Range $3.96 ▼ $11.46 Price Target $7.33 Add to Watchlist Bausch Health NYSE: BHC stock has been on a wild ride recently, with a dramatic surge in value over the last month. The catalyst for this surge is a wave of rumors suggesting that Bausch + Lomb NYSE: BLCO, Bausch Health's spinoff eye care business, is considering a buyout. This potential sale has sparked significant interest among investors, as it could lead to a mu ...

Shares of Bausch Health, Inc. (BHC) gained 14.7% in a week on reports of refinancing its debt to enable the impending sale of its eye care company, Bausch + Lomb (BLCO) . The industry declined 0.6% during this timeframe. The sale, intended to separate both companies, is stuck for quite some time now. Hence, reports of BHC moving forward have encouraged investors. Image Source: Zacks Investment Research BHC's Plans to Separate BLCO In August 2020, BHC announced its plan to separate its eye health business, c ...

Tom Yeung here with your Sunday Digest. During the early 1990s real estate crisis, the Marriott Corp. hotel chain found itself in trouble. The company had overexpanded during the boom times of the 1980s, and the ensuing crash had left it with over a hundred unsellable hotels in an overbuilt market. To save the firm, Chief Financial Officer Stephen Bollenbach created a breakup plan for the hotel chain. Under the agreement, Marriott would keep its lucrative management business (the "good" Marriott), while spi ...

Group 1 - The article emphasizes the importance of market research and financial analytics in the biotech, healthcare, and pharma sectors, highlighting the value of subscription services for investors [1][2] - It mentions that the investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, and product sales forecasts for major pharmaceutical companies [2] - The article notes that the analyst has extensive experience in the biotech field, having covered over 1,000 companies and produced detailed reports [2] Group 2 - The article includes a disclosure stating that the analyst does not hold any stock or derivative positions in the mentioned companies but may initiate a long position in the near future [3] - It clarifies that past performance is not indicative of future results and that no specific investment recommendations are being made [4]

Bausch Health (BHC) shares rallied 11.7% in the last trading session to close at $8.02. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 23.2% gain over the past four weeks. Bausch stock witnessed a rally after a Bloomberg report said that the company is working with Jefferies Financial Group to explore refinancing some of its debt. The debt refinancing is expected to help the company in the impending spinoff ...

In January, I wrote an article in which I recommended Bausch + Lomb (NYSE: BLCO ) on the grounds that it was trading near its 52-week lows and looked like a good rebound candidate. BLCO stock has I'm Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Magazine and the Quincy Institute for Responsible Statecraft. I have ...

CHICAGO, ILLINOIS - MAY 05: Bausch + Lomb eye vitamins are offered for sale at a drug store on May 05, 2022 in Chicago, Illinois. Bausch + Lomb parent company Bausch Health is spinning off the eye-care company with an upcoming IPO which will list on the New York Stock Exchange and TSX with the ticker symbol "BLCO". (Photo by Scott Olson/Getty Images) In May 2022 , Bausch + Lomb (BLCO) was spun off as a separate publicly traded entity, but it continues to be a core part of Bausch Health's business through it ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Core Viewpoint - Bausch Health Companies Inc. reported second-quarter adjusted earnings per share of 89 cents, matching the Zacks Consensus Estimate, with total revenues of $2.4 billion, reflecting an 11% year-over-year increase and surpassing the consensus estimate of $2.3 billion [1][2]. Revenue Breakdown - Salix revenues were $558 million, flat year-over-year, with Xifaxan revenues increasing by 10%, offset by declines in Relistor and Trulance [3]. - International revenues reached $276 million, up 7% year-over-year, driven by strong growth in Canada and Latin America, exceeding the Zacks Consensus Estimate [4]. - Diversified Product revenues amounted to $251 million, a 10% increase from the previous year, with notable growth in dermatology sales [5][7]. - Solta Medical reported revenues of $102 million, a 16% year-over-year increase, primarily driven by strong results in Asia Pacific [8]. - Bausch + Lomb revenues totaled $1.21 billion, up 17% year-over-year, with growth across all business units [9]. Pipeline Development - The phase II study on amiselimod for ulcerative colitis has completed enrollment, and a phase III study protocol has been submitted to the FDA [10]. - Phase III studies for rifaximin in hepatic encephalopathy are ongoing, with regulatory submissions for next-generation Fraxel expected in the second half of the year [11]. - The Clear and Brilliant Touch program is advancing with regulatory submissions planned for 2024 [12]. Legal Updates - The U.S. Court of Appeals affirmed a decision preventing Norwich Pharmaceuticals from obtaining approval for a generic version of Xifaxan until October 2029 [13]. - BHC filed a patent infringement lawsuit against Norwich and Amneal Pharmaceuticals regarding generic versions of Xifaxan [14][15]. 2024 Guidance - The company raised its revenue guidance for 2024 to a range of $9.4-$9.65 billion, driven by an increase in Bausch + Lomb's expectations [16]. Market Performance - Despite the positive earnings report, BHC's shares have declined 24% year-to-date, contrasting with the industry growth of 14.8% [2][17].